Clinigen Group plc Clinigen signs agreement with BioQ Pharma
December 15 2016 - 2:00AM
RNS Non-Regulatory
TIDMCLIN
Clinigen Group plc
15 December 2016
15 December 2016
CLINIGEN GROUP PLC
Clinigen signs Global Access agreement for BioQ Pharma's
post-operative pain management product, Ropivacaine Readyfusor
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services company, announces that its Idis
Global Access (GA) division has signed a supply and distribution
agreement with BioQ Pharma, a developer of large volume
ready-to-use infusible products. The deal covers the on-demand
supply and distribution of BioQ Pharma's pre-filled Ropivacaine
Readyfusor for post-operative pain management in Europe, excluding
France and Germany.
Under the terms of the agreement, Idis GA will make the
Ropivacaine Readyfusor available, prior to it receiving its
national marketing authorisation, on an exclusive on-demand basis
to physicians and pharmacists in the UK. Idis GA will also supply
the product to other European territories prior to approval and
will manage distribution to provide ethical access to the
product.
The Ropivacaine Readyfusor is a disposable, single use infusion
product which is pre-filled by the manufacturer with 0.2%
Ropivacaine, a non-narcotic local anaesthetic. It is a
self-contained drug and administration system for delivery at the
point of care, activated by a single touch. The Ropivacaine
Readyfusor contains a sterile drug that is hermetically sealed
until time of use.
The ready-to-use product delivers Ropivacaine at a
pre-determined rate to provide pain control for at least
48 hours after surgery.
Steve Glass, Chief Commercial Officer (North America and Europe)
of Clinigen said:
"As the global leaders in providing trusted, ethical access to
unlicensed medicines, this agreement means that we can enable
healthcare professionals to access the Ropivacaine Readyfusor
on-demand for their patients.
"This partnership with BioQ Pharma marks another important
supply agreement for Idis GA. It demonstrates the continuing demand
from pharmacists and physicians for a compliant route to obtain
medicines that are unlicensed or unavailable in their country.
There is also an increase in engagement from manufacturers to work
with us to help provide continuous access to their products, to
better serve patients with unmet medical needs."
Walter Cleymans, Vice President of Europe of BioQ said:
"We are pleased to make Ropivacaine Readyfusor available to
patients in Europe with the assistance of Idis GA. The Readyfusor
is intended to provide effective pain relief following surgery,
while providing a convenient, self-contained, and ready-to-use
presentation that should reduce the number of steps needed to
administer the drug to the patient."
The Ropivacaine Readyfusor comes completely ready-to-use from
the manufacturer, it is intended to help avoid filling errors and
breaches in sterility often associated with conventional
elastomeric "pain pumps". The Ropivacaine Readyfusor's proprietary
design precludes the risk of overdosing due to delivery
malfunctions. The product should be prescribed post-surgically for
medically appropriate procedures that require at least 48 hours of
pain relief. Ropivacaine can be administered as a continuous
surgical site infusion or continuous peripheral nerve block.
Healthcare professionals can obtain details about the
Ropivacaine Readyfusor pre-filled infusion product by emailing
customer.services@clinigengroup.com.
- Ends-
Clinigen Group plc Tel: +44 (0) 1283 495 010
Shaun Chilton, Group Chief Executive
Officer
Steve Glass, Chief Commercial Officer
(North America and Europe)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard (Corporate
Broking)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Instinctif Partners (media relations Tel: +44 (0) 20 7457 2020
- Clinigen)
Melanie Toyne-Sewell / Jen Lewis Email: clinigen@instinctif.com
BioQ Pharma
Walter Cleymans, Vice President,
Europe Tel: +32 474 053 253
Email: walter.cleymans@bioqpharma.com
Josh Kriesel, Ph.D., President and
CEO Tel: +1 415 336 6496
Email: josh.kriesel@bioqpharma.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical
trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions: Idis Managed Access runs early access programs
for innovative new medicines. Idis Global Access and Link
Healthcare work directly with healthcare professionals to enable
compliant access to unlicensed medicines on a global basis and
niche essential licensed and generic medicines across Australasia,
Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital
commercial products.
For more information, please visit www.clinigengroup.com.
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty
pharmaceutical company focused on developing and commercializing
ready-to-use infusible pharmaceuticals. The Company's infusion
platform is intended to address some of the most pressing unmet
needs in drug infusion today: cost, medication error, sterility,
efficiency, and patient quality of life. BioQ Pharma's objective is
to set a new standard of care in the presentation and
administration of infusible pharmaceuticals via the Company's
proprietary unit-dose infusion systems that can be deployed quickly
and conveniently at the point of care with one touch. The Company
is ISO13485 certified. BioQ Pharma's existing commercial
collaborators and strategic partners include Novartis' Sandoz unit,
Cipla, Lee's Pharm, Galen Limited, Lunatus and West Pharmaceutical
Services.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAPALFAFKFFF
(END) Dow Jones Newswires
December 15, 2016 02:00 ET (07:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024